On August 11, 2015 Hospira Japan Co., Ltd. reported that the additional indication of "Unresectable advanced/recurrent gastric cancer" for Oxaliplatin I.V. lnfusion [Hospira] in 50mg and 100mg has been approved by the Ministry of Health, Labour and Welfare (MHLW) in Japan (Press release, Hospira, AUG 11, 2015, View Source;p=RssLanding&cat=news&id=2078684 [SID:1234507210]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About the Products
[Product name]
1. Oxaliplatin I.V. lnfusion 50mg/10mL [Hospira]
2. Oxaliplatin I.V. lnfusion 100mg/20mL [Hospira]

[Ingredient]
Irinotecan hydrochloride hydrate

[Therapeutic category]
Anticancer drug

[Indications] (*The underlined text represents the additional indication)

Unresectable advanced/recurrent colorectal cancer,
Supplementary postoperative chemotherapy for colon cancer, Inoperable pancreatic cancer
Unresectable advanced/recurrent gastric cancer

Hospira Japan has a partnership co-promoting oncology generic products with Mochida Pharmaceutical in Japan.

We are committed to contribute to healthcare in Japan by providing value-added products with its global broad portfolio, and meet the expectations of patients and healthcare professionals.